Your session is about to expire
← Back to Search
Other
LIQUICURE for Fungal Nail Infection (CT001 Trial)
N/A
Waitlist Available
Led By Beth Goldstein, MD
Research Sponsored by Chesson Laboratory Associates, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
CT001 Trial Summary
There is a major clinical need for an inexpensive topically-applied product that can inhibit the growth of the dermatophytes that cause nail fungus. Chesson Labs has developed LIQUICURE with a longer drying/curing time that will allow better nail penetration or adsorption. Though the product may have inherent antimicrobial activity, the product does not contain a drug or antimicrobial agent. Consistent use of LIQUICURE as described will clear fungal nail infection. Clearing of nail fungal infection is defined by negative dermatophyte culture and visual improvement in nail characteristics within six months, with few, if any product-related adverse events.
CT001 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ six months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clearance of fungal nail infection defined by negative culture and improvement in visual nail characteristics
Freedom from major product-related adverse events for the duration of the feasibility phase.
Secondary outcome measures
Time to clearance of infection
CT001 Trial Design
1Treatment groups
Experimental Treatment
Group I: LIQUICUREExperimental Treatment1 Intervention
Medical Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LIQUICURE
2008
N/A
~70
Find a Location
Who is running the clinical trial?
Chesson Laboratory Associates, IncLead Sponsor
Beth Goldstein, MDPrincipal InvestigatorCentral Dermatology
Share this study with friends
Copy Link
Messenger